Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Dnu3.5
Danuglipron – Forschung
Überwiegend Mechanismus / Beobachtung
12 begutachtete Studien
Was die Evidenz sagt
Überwiegend Mechanismus / Beobachtung
Die meisten Studien zu Danuglipron sind mechanistisch oder beobachtend statt RCTs, die einen klinischen Effekt messen — betrachte die Ergebnisse als vorläufig.
Die meiste Evidenz stammt aus hochwertigen Meta-Analysen und randomisierten Studien, veröffentlicht 2021–2026 mit einer typischen Studiengröße von 5,766 Teilnehmenden.
Basierend auf 12 Studien · 3 Meta-Analysen · 5 RCTs · 7,220 Teilnehmende insgesamt
Konfidenz
Hohe Konfidenz
Nach Outcome
Glucose & glycemic controlDosisabhängige HbA1c-Senkungen bei Typ-2-Diabetes — bis zu placebobereinigt -1,16 % nach 16 Wochen (Phase 2b) · Über ~16 Wochen
Überwiegend Mechanismus / Beobachtung11 Studien
Weight & obesityPlacebobereinigter Gewichtsverlust von bis zu ~-4,2 kg bei T2D und -5,0 % bis -12,9 % bei Adipositas über 26–32 Wochen, wobei die Verträglichkeit die Dosierung begrenzte · Über ~26–32 Wochen
Überwiegend Mechanismus / Beobachtung7 Studien
Safety & tolerability
Zu wenige bewertete Studien2 Studien
Aktives Forschungsgebiet
12 Studien in den letzten 5 Jahren · Neueste Meta-Analyse: 2026
20212026
1Meta-Analyse2026
Li L, Shui D, Zhang X, Tan B, Deng Y · Front Endocrinol (Lausanne) (2026)
However, both danuglipron and orforglipron were associated with the occurrence of treatment-related adverse events and gastrointestinal adverse events (AEs).
Einfach gesagt: Conclusion HiD oral semaglutide and orforglipron demonstrated the most consistent and substantial weight reductions though low-to-moderate certainty and lack of head-to-head comparisons constrain comparative inference.
Kamrul-Hasan ABM, Ashraf H, Nagendra L, Khalil I, Chatterjee S, Dutta D, Haq T, Alanazi MA, Pappachan JM. · Obesity science & practice (2026)
The primary outcome was percent change in body weight, with secondary outcomes including other weight measures and weight thresholds.
All agents except low-dose (LoD) lotiglipron outperformed placebo in percent body weight reduction; high-dose (HiD) semaglutide (MD -11.6%) and orforglipron (MD -11.8%) showed the greatest effects.
Danuglipron HiD, semaglutide HiD, and semaglutide LoD ranked highest for ≥ 5%, ≥ 10%, and ≥ 15% weight loss, respectively.
Einfach gesagt: Our review provides a comprehensive overview of the approved and emerging hormone-based AOMs, highlighting the diversity of options that might become available in the near future.
Sidrak WR, Kalra S, Kalhan A. · Indian journal of endocrinology and metabolism (2024)
Tirzepatide, a dual agonist for the glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors, has been observed to be associated with a significant placebo-subtracted weight reduction of 17.8% in a 72-week randomized controlled trial.
Retatrutide, a GLP1R/GCGR/GIPR tri-agonist, has been associated with a placebo-subtracted weight reduction of -22.1% in a 48-week phase-II trial.
Three long-acting GLP1R/glucagon receptor (GCGR) dual agonists, namely Survodutide, Mazdutide, and Pemvidutide, exhibited significant weight loss in clinical trials.
Einfach gesagt: These pharmacological agents are having significant impact on glycaemic control and obesity and on their co-morbidities.
Camilleri M, Acosta A. · British journal of pharmacology (2024)
Oral semaglutide (administered daily) is approved for type 2 diabetes mellitus and is on track for regulatory review for obesity.
The review includes specifically perspectives on the effects of these mechanisms and pharmacological agents on gastric emptying, which contribute to satiation and weight loss, in addition to the established evidence on effects on central mechanisms controlling appetite.
In the future, it is anticipated that small molecule GLP-1 receptor agonists (e.g., oral danuglipron) will be developed for treating obesity.
Einfach gesagt: Novel GLP-1RAs led to significant reduction in HbA1c... (MD = -1.03%)... and significantly higher odds of gastrointestinal, treatment-emergent adverse events (OR = 2.57...) and adverse events leading to discontinuation (OR = 2.89...).
Karakasis P, Patoulias D, Pamporis K, Stachteas P, Bougioukas KI, Klisic A, Fragakis N, Rizzo M. · Metabolism (2023)
Systematic review and random-effects meta-analysis of 7 RCTs (n=1037) of the oral small-molecule GLP-1 agonists orforglipron and danuglipron in T2D and/or obesity
Significant HbA1c reduction (-1.03%) and weight reduction (-3.26 kg in T2D; -7.52 kg in obesity) vs controls; all RCTs low risk of bias (RoB2)
Neutral on severe hypoglycemia and serious adverse events, but ~2.57x higher GI adverse events and ~2.89x higher discontinuation vs controls
Einfach gesagt: Herein, we describe the discovery of the orally bioavailable, small-molecule, GLP-1R agonist PF-06882961 (danuglipron)... a binding pocket requiring a primate-specific tryptophan 33 residue.
Griffith DA, Edmonds DJ, Fortin JP, Kalgutkar AS, Kuzmiski JB, Loria PM, Saxena AR, et al. · J Med Chem (2022)
Discovery and medicinal-chemistry paper for PF-06882961 (danuglipron): a 5-fluoropyrimidine chemotype optimized from a sensitized high-throughput screen
A cryo-EM structure and mutagenesis revealed a binding pocket requiring a primate-specific tryptophan-33 residue — explaining insulin increases in primates but not rodents
Foundational mechanism/discovery paper — establishes danuglipron as a true oral non-peptide GLP-1R agonist